<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00031798</url>
  </required_header>
  <id_info>
    <org_study_id>REBACDR0000069227</org_study_id>
    <secondary_id>CCCWFU-97600</secondary_id>
    <secondary_id>NCI-P02-0211</secondary_id>
    <nct_id>NCT00031798</nct_id>
  </id_info>
  <brief_title>Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors</brief_title>
  <official_title>A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <brief_summary>
    <textblock>
      RATIONALE: Methylphenidate may decrease side effects of radiation therapy. It is not yet
      known if methylphenidate is effective in improving quality of life in patients with primary
      or metastatic brain tumors.

      PURPOSE: Randomized phase III trial to determine the effectiveness of methylphenidate in
      improving quality of life in patients who have brain tumors and are undergoing radiation
      therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the effect of d-methylphenidate on fatigue in patients receiving radiotherapy
           for primary or metastatic brain tumors.

        -  Determine the effect of this drug on the quality of life of these patients.

        -  Determine the effect of this drug on depression in these patients.

        -  Determine the effect of this drug on global neurocognitive function, including attention
           and concentration, memory, language, visuospatial skills, and executive function, in
           these patients.

      OUTLINE: This is a randomized, placebo-controlled, double-blind, multicenter study. Patients
      are stratified by tumor type (primary vs metastatic), treatment (radiotherapy vs radiotherapy
      and chemotherapy), and Karnofsky performance status (70% or 80% vs 90% or 100%). Patients are
      randomized to one of two treatment arms.

      All patients undergo radiotherapy over weeks 1-4.

        -  Arm I: Patients receive oral d-methylphenidate twice daily on weeks 1-12.

        -  Arm II: Patients receive oral placebo twice daily on weeks 1-12. In both arms, quality
           of life is assessed at baseline, at the end of radiotherapy, and at 4, 8, and 12 weeks
           after radiotherapy.

      Patients are followed at 4 weeks.

      PROJECTED ACCRUAL: A total of 200 patients (100 per treatment arm) will be accrued for this
      study within 18 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual; loss of funding
  </why_stopped>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Cognitive/Functional Effects</condition>
  <condition>Depression</condition>
  <condition>Fatigue</condition>
  <condition>Quality of Life</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylphenidate hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed metastatic brain tumor OR

          -  Histologically confirmed primary brain tumor

               -  Glioblastoma multiforme

               -  Anaplastic astrocytoma

               -  Anaplastic oligodendroglioma

               -  Anaplastic mixed oligoastrocytoma

               -  Low-grade glioma

               -  Meningioma

               -  Ependymoma

          -  Planned external beam cranial radiotherapy (partial or whole brain) with a total dose
             of at least 25 Gy in at least 10 fractions of 180-300 cGy each

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 70-100%

        Life expectancy:

          -  At least 3 months

        Hematopoietic:

          -  WBC ≥ 1,500/mm^3

          -  Hemoglobin ≥ 10.0 g/dL

          -  Platelet count ≥ 75,000/mm^3

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Cardiovascular:

          -  No hypertension or other cardiovascular disease requiring antihypertensives and/or
             other cardiovascular medications

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other serious medical or psychiatric illness that would preclude study
             participation

          -  No hypersensitivity to study drug

          -  No history of steroid psychosis

          -  No family history of or active Tourette's Syndrome

          -  No prior or active glaucoma

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Prior or concurrent chemotherapy allowed

        Endocrine therapy:

          -  Concurrent steroids allowed

        Radiotherapy:

          -  See Disease Characteristics

          -  Prior radiotherapy allowed except to brain (including stereotactic radiosurgery)

          -  No concurrent craniospinal axis radiotherapy

        Surgery:

          -  Not specified

        Other:

          -  No prior or concurrent medications for attention deficit disorder, anxiety disorder,
             schizophrenia, or substance abuse

          -  No concurrent anti-depressants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward G. Shaw, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Western Regional, Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006-2726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Central Illinois</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - LSU Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Southeast Cancer Control Consortium</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534-9479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Upstate Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fatigue</keyword>
  <keyword>depression</keyword>
  <keyword>quality of life</keyword>
  <keyword>cognitive/functional effects</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult tumors metastatic to brain</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult meningioma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult myxopapillary ependymoma</keyword>
  <keyword>adult ependymoblastoma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult subependymoma</keyword>
  <keyword>adult grade III meningioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult grade II meningioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

